Identification of immature and mature myeloma cells in the bone marrow of human myelomas
- PMID: 8329711
Identification of immature and mature myeloma cells in the bone marrow of human myelomas
Abstract
With regard to the expression of adhesion molecules, human myeloma cells freshly isolated from bone marrow were heterogeneous. By two-color analysis with anti-VLA-5 antibody (PE staining) and FITC-labeled anti-CD38 antibody, we found all myeloma cells located at CD38-strong positive (CD38++) fraction and identified two subpopulations among these myeloma cells: CD38++ VLA-5-(VLA-5-) myeloma cells and CD38++ VLA-5+ (VLA-5+) myeloma cells. To clarify the biologic character of these two subpopulations, the morphology, in vitro proliferative activity and in vitro M-protein secretion were examined in each fraction isolated by the purification procedure or a cell sorter. Morphologic examination showed that VLA-5- myeloma cells were mostly immature or plasmablastic and VLA-5+ cells were mature myeloma cells. Furthermore, VLA-5- myeloma cells proliferated markedly in vitro and responded to interleukin 6 (IL-6), a growth factor for myeloma cells, while VLA-5+ myeloma cells showed very low uptakes of 3H-thymidine and no responses to IL-6 but secreted higher amounts of M-protein (immunoglobulin) in vitro significantly. Therefore, we could clarify here heterogeneity of human myeloma cells in the bone marrow with regard to the expression of VLA-5, one of integrin adhesion molecules; VLA-5- myeloma cells were proliferative immature cells and VLA-5+ cells were mature myeloma cells.
Similar articles
-
[Myeloma precursor cells].Rinsho Ketsueki. 1993 Apr;34(4):433-8. Rinsho Ketsueki. 1993. PMID: 7685432 Japanese.
-
Expression of beta 1 integrins (very late antigens-4 and -5) on myeloma cells and clinical correlates in patients with multiple myeloma.J Int Med Res. 1998 Jan-Feb;26(1):37-42. doi: 10.1177/030006059802600104. J Int Med Res. 1998. PMID: 9513075
-
High proportions of VLA-5- immature myeloma cells correlated well with poor response to treatment in multiple myeloma.Br J Haematol. 1995 Dec;91(4):860-4. doi: 10.1111/j.1365-2141.1995.tb05401.x. Br J Haematol. 1995. PMID: 8547130
-
Biological significance of heterogeneity in human myeloma cells.Int J Hematol. 1998 Dec;68(4):363-70. doi: 10.1016/s0925-5710(98)00089-9. Int J Hematol. 1998. PMID: 9885436 Review.
-
[Phenotypic analysis of myeloma cells].Nihon Rinsho. 1995 Mar;53(3):574-9. Nihon Rinsho. 1995. PMID: 7699888 Review. Japanese.
Cited by
-
Establishment of a monoclonal antibody to plasma cells: a comparison with CD38 and PCA-1.Clin Exp Immunol. 1994 May;96(2):370-5. doi: 10.1111/j.1365-2249.1994.tb06569.x. Clin Exp Immunol. 1994. PMID: 8187346 Free PMC article.
-
Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130.J Exp Med. 1994 Apr 1;179(4):1343-7. doi: 10.1084/jem.179.4.1343. J Exp Med. 1994. PMID: 8145046 Free PMC article.
-
An increase in MPC-1- and MPC-1-CD45+ immature myeloma cells in the progressive states of bone marrow plasmacytosis: the revised phenotypic classification of monoclonal marrow plasmacytosis (MOMP-2005).Int J Hematol. 2006 Jan;83(1):39-43. doi: 10.1532/IJH97.05112. Int J Hematol. 2006. PMID: 16443550
-
Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma.Med Oncol. 2002;19(2):87-104. doi: 10.1385/MO:19:2:87. Med Oncol. 2002. PMID: 12180485
-
Immunotherapies targeting CD38 in Multiple Myeloma.Oncoimmunology. 2016 Aug 5;5(11):e1217374. doi: 10.1080/2162402X.2016.1217374. eCollection 2016. Oncoimmunology. 2016. PMID: 27999737 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials